| Literature DB >> 35380712 |
John L Marshall1, Beth N Peshkin2, Takayuki Yoshino3, Jakob Vowinckel4, Håvard E Danielsen5, Gerry Melino6, Ioannis Tsamardinos7, Christian Haudenschild8, David J Kerr9, Carlos Sampaio10, Sun Young Rha11, Kevin T FitzGerald12, Eric C Holland13, David Gallagher14, Jesus Garcia-Foncillas15, Hartmut Juhl16.
Abstract
Within the last decade, the science of molecular testing has evolved from single gene and single protein analysis to broad molecular profiling as a standard of care, quickly transitioning from research to practice. Terms such as genomics, transcriptomics, proteomics, circulating omics, and artificial intelligence are now commonplace, and this rapid evolution has left us with a significant knowledge gap within the medical community. In this paper, we attempt to bridge that gap and prepare the physician in oncology for multiomics, a group of technologies that have gone from looming on the horizon to become a clinical reality. The era of multiomics is here, and we must prepare ourselves for this exciting new age of cancer medicine.Entities:
Keywords: artificial intelligence; cancer; digital pathology; genomics; machine learning; multiomics; proteomics; transcriptomics
Mesh:
Year: 2022 PMID: 35380712 PMCID: PMC8982374 DOI: 10.1093/oncolo/oyab048
Source DB: PubMed Journal: Oncologist ISSN: 1083-7159